Oxford Biomedica PLC OXB Present at 3rd Annual Regen Med Investor Day
March 20 2015 - 3:00AM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
20 March 2015
Oxford BioMedica to Present at 3(rd) Annual Regen Med Investor
Day
London, UK - 20 March 2015: Oxford BioMedica plc ("Oxford
BioMedica" or "the Company") (LSE:OXB), a leading gene and cell
therapy company, announces that Dr Paul Blake, Chief Development
Officer, will present at the 3(rd) Annual Regen Med Investor Day,
being held Wednesday, March 25, 2015 in New York City.
Dr. Blake will present at 2:40pm ET / 6.40pm GMT to attending
investors. During his presentation Dr. Blake will discuss Oxford
BioMedica's expertise in the clinical development and manufacturing
of gene and cell therapies.
Details of the Oxford BioMedica presentation are as follows:
Event: ARM's Regen Med Investor Day
Date: March 25, 2015
Time: 2.40pm ET / 6.40pm GMT
Location: Metropolitan Club, One East 60th Street, New York, NY 10022
At the time of the ARM Regen Med Investor Day, a live-streaming
webcast of all panels and company presentations will be available
at: http://www.arminvestorday.com/webcast and will be published on
the event's website shortly after the conference as well as on the
company's website in the media section:
http://www.oxfordbiomedica.co.uk/webcasts-and-audio/.
- Ends -
For further information, please
contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive Officer 783 000
Tim Watts, Chief Financial Officer
Consilium Strategic Communications Tel: +44 (0)20
Mary-Jane Elliott/Matthew Neal/Chris 3709 5700
Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell
therapy company with an unrivalled portfolio of gene therapy
products in development and a platform of exclusive and pioneering
technologies with which it designs, develops and manufactures
unique gene-based medicines for some of world's largest
pharmaceutical companies. Leveraging its proprietary LentiVector(R)
IP and gene delivery system technology platform and unique tumour
antigen (5T4), Oxford BioMedica is advancing its pipeline of seven
gene therapy products addressing diseases for which there are
currently no treatments or that are inadequately treated today,
including ocular and central nervous system disorders. OXB
Solutions, the Company's industry-leading manufacturing and
development business, provides services to collaborators and
partners working in gene and cell therapy, including Novartis and
Immune Design Corp. In addition, the Company has licenced products
and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich,
Biogen Idec, Emergent BioSolutions and ImaginAb. Further
information is available at www.oxfordbiomedica.co.uk and
www.oxbsolutions.co.uk .
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGUUCWUPAGMB
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Sep 2023 to Sep 2024